A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity


Phase 3 Results N/A

Eligibility Criteria

Inclusion Criteria

1. Male or female adult patients
2. ≥ 6 weeks since the last stroke

Exclusion Criteria

1.Patients with diagnosed neuromuscular disorders such as Lamber-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis.